MedTrace Logo

Longitudinal Hemostatic Profile After Stopping Estroprogestative Contraceptives

NCT03949985 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2021-05-21

No results posted yet for this study

Summary

This prospective cohort evaluates the longitudinal profile of hemostatic biomarkers during the first 3 months after having stopped a combined oral contraceptive.

Conditions

  • Venous Thromboembolism
  • Contraception

Interventions

OTHER

Tests of biological hemostatic profile associated with contraceptives

Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)

Sponsors & Collaborators

  • University Hospital, Geneva

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-08
Primary Completion
2020-09-14
Completion
2020-09-14
FDA Drug
Yes

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03949985 on ClinicalTrials.gov